NASDAQ:KMDA Kamada (KMDA) Stock Price, News & Analysis → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free KMDA Stock Alerts $5.10 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$5.01▼$5.1250-Day Range$4.90▼$6.4252-Week Range$4.08▼$6.53Volume5,342 shsAverage Volume20,311 shsMarket Capitalization$293.10 millionP/E Ratio34.00Dividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Kamada alerts: Email Address Kamada MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside115.7% Upside$11.00 Price TargetShort InterestHealthy0.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth78.26%From $0.23 to $0.41 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.03 out of 5 starsMedical Sector174th out of 909 stocksPharmaceutical Preparations Industry64th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingKamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKamada has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.13% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently decreased by 10.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKamada does not currently pay a dividend.Dividend GrowthKamada does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KMDA. Previous Next 1.8 News and Social Media Coverage News SentimentKamada has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kamada this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kamada insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.38% of the stock of Kamada is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Kamada are expected to grow by 78.26% in the coming year, from $0.23 to $0.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kamada is 34.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Kamada is 34.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 240.89.Price to Book Value per Share RatioKamada has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Kamada Stock (NASDAQ:KMDA)Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Read More KMDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KMDA Stock News HeadlinesApril 23, 2024 | americanbankingnews.comKamada (NASDAQ:KMDA) Shares Pass Below 200 Day Moving Average of $5.46April 19, 2024 | msn.comKamada Ekadashi 2024: When is Kamada Ekadashi? Know date, Ekadashi tithi, shubh muhurat, Parana time and significanceApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 19, 2024 | msn.comKamada Ekadashi 2024: Know significance, spiritual benefits, rituals and moreApril 15, 2024 | americanbankingnews.comKamada Ltd. (NASDAQ:KMDA) Short Interest Down 10.4% in MarchMarch 19, 2024 | finance.yahoo.comKMDA Aug 2024 10.000 callMarch 19, 2024 | finance.yahoo.comKMDA May 2024 5.000 callMarch 16, 2024 | finance.yahoo.comKMDA Apr 2024 10.000 callApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 13, 2024 | finance.yahoo.comKMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…March 7, 2024 | benzinga.comPreview: Kamada's EarningsMarch 7, 2024 | markets.businessinsider.comStrategic Partnerships and Product Portfolio Expansion Poise Kamada for Robust GrowthMarch 7, 2024 | finance.yahoo.comKamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | msn.comFootball: Kubo, Kamada exit Champions League as Sociedad, Lazio loseMarch 6, 2024 | washingtonpost.comKamada: Q4 Earnings SnapshotMarch 6, 2024 | investorplace.comKMDA Stock Earnings: Kamada Beats EPS, Misses Revenue for Q4 2023March 6, 2024 | globenewswire.comKamada Issues 2024 CEO Letter to ShareholdersMarch 6, 2024 | globenewswire.comKamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and ProfitabilityFebruary 28, 2024 | globenewswire.comKamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024February 22, 2024 | benzinga.comKamada Stock (NASDAQ:KMDA) Dividends: History, Yield and DatesFebruary 8, 2024 | wsj.comKamada Ltd.January 31, 2024 | stocknews.com3 Pharma Gems Driving Profits NowJanuary 12, 2024 | stocknews.comWill These 3 Pharma Stocks Become Gainers in 2024?December 8, 2023 | seekingalpha.comKamada: Kedrion Deal Locks In GrowthDecember 7, 2023 | msn.comKMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…December 7, 2023 | finance.yahoo.comKEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®December 7, 2023 | marketwatch.comKamada Shares Hit 52-Week High After Extending Agreement With KedrionSee More Headlines Receive KMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/24/2024Next Earnings (Estimated)5/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KMDA CUSIPN/A CIK1567529 Webwww.kamada.com Phone(728) 940-6472Fax972-8940-6473Employees378Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+115.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.15 Trailing P/E Ratio34.00 Forward P/E Ratio22.17 P/E GrowthN/ANet Income$8.28 million Net Margins5.81% Pretax Margin5.91% Return on Equity5.66% Return on Assets3.57% Debt Debt-to-Equity RatioN/A Current Ratio3.43 Quick Ratio1.64 Sales & Book Value Annual Sales$142.52 million Price / Sales2.06 Cash Flow$0.43 per share Price / Cash Flow11.84 Book Value$4.25 per share Price / Book1.20Miscellaneous Outstanding Shares57,470,000Free Float36,726,000Market Cap$293.10 million OptionableOptionable Beta1.04 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Amir London (Age 55)Chief Executive Officer Comp: $611kMr. Chaime Orlev (Age 54)Chief Financial Officer Comp: $387kMr. Eran Nir (Age 51)Chief Operating Officer Comp: $332kMr. Jon R. Knight (Age 58)Vice President of US Commercial Operations Comp: $307kMr. Boris Gorelik (Age 43)Vice President of Business Development & Strategic Programs Comp: $410kMr. David Tsur (Age 74)Co-Founder & Independent Deputy Chairman of the Board Comp: $252kMr. Nir Livneh B.A. (Age 44)L.L.B., VP, General Counsel & Corporate Secretary Ms. Hanni Neheman (Age 54)Vice President of Marketing & Sales Ms. Liron Reshef (Age 52)Vice President of Human Resources Ms. Shavit BeladevVice President of Kamada PlasmaMore ExecutivesKey CompetitorsNeoleukin TherapeuticsNASDAQ:NLTXErascaNASDAQ:ERASVerrica PharmaceuticalsNASDAQ:VRCAContineum TherapeuticsNASDAQ:CTNMRenovaroNASDAQ:RENBView All CompetitorsInstitutional OwnershipAristides Capital LLCBought 16,635 shares on 2/13/2024Ownership: 0.099%Altshuler Shaham LtdSold 132,330 shares on 2/7/2024Ownership: 0.231%Calton & Associates Inc.Bought 18,124 shares on 2/7/2024Ownership: 0.032%Y.D. More Investments LtdBought 15,000 shares on 2/6/2024Ownership: 0.050%EWA LLCBought 11,851 shares on 2/5/2024Ownership: 0.021%View All Institutional Transactions KMDA Stock Analysis - Frequently Asked Questions Should I buy or sell Kamada stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares. View KMDA analyst ratings or view top-rated stocks. What is Kamada's stock price target for 2024? 1 brokers have issued 1 year target prices for Kamada's stock. Their KMDA share price targets range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 115.7% from the stock's current price. View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts. How have KMDA shares performed in 2024? Kamada's stock was trading at $6.12 at the beginning of 2024. Since then, KMDA shares have decreased by 16.7% and is now trading at $5.10. View the best growth stocks for 2024 here. Are investors shorting Kamada? Kamada saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 40,300 shares, a decline of 10.4% from the March 15th total of 45,000 shares. Based on an average trading volume of 23,000 shares, the days-to-cover ratio is currently 1.8 days. Approximately 0.1% of the shares of the stock are short sold. View Kamada's Short Interest. When is Kamada's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our KMDA earnings forecast. How were Kamada's earnings last quarter? Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Wednesday, March, 6th. The biotechnology company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.04. The biotechnology company had revenue of $36.43 million for the quarter, compared to analyst estimates of $37.71 million. Kamada had a net margin of 5.81% and a trailing twelve-month return on equity of 5.66%. What guidance has Kamada issued on next quarter's earnings? Kamada issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $156.0 million-$160.0 million, compared to the consensus revenue estimate of $166.1 million. What other stocks do shareholders of Kamada own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW). How do I buy shares of Kamada? Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KMDA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
